This new review article highlights the crucial role of GATA6, a transcription factor, in pancreatic ductal adenocarcinoma (PDA). The article explores GATA6’s dual role in cancer progression and its potential as a biomarker and treatment target.
Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate of only 5%. This study finds that higher GATA6 expression correlates with better tumor differentiation and improved patient outcomes, while low GATA6 levels are linked to aggressive basal-like PDA, a chemotherapy-resistant subtype.
It is also revealed that GATA6 influences multiple cancer-related pathways—including Wnt, Notch, Hedgehog, TGF-β, and VEGFR—helping to regulate tumor development. While GATA6 overexpression can promote cancer growth, it also helps maintain…